Nasus Pharma (NSRX) provided a business update highlighting recent Phase 2 results for NS002, its intranasal powder epinephrine product candidate for anaphylaxis. The company reported topline results demonstrating statistically significant improvements in time to therapeutic threshold compared to EpiPen. Nasus is advancing NS002 toward a pivotal clinical study expected to initiate in the Q4 of 2026. “Following the compelling topline Phase 2 results of NS002, we are advancing our intranasal epinephrine powder formulation towards a pivotal study planned to initiate in the fourth quarter of this year,” said Dan Teleman, CEO of Nasus Pharma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSRX:
- Nasus Pharma’s NS002 Demonstrates Consistent Early Advantage in Epinephrine Delivery (NYSE: NSRX)
- Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
- Nasus Pharma’s NS002 Outperforms EpiPen in Phase 2 Anaphylaxis Study, Pivotal Trial Planned for Late 2026
- Nasus Pharma announces topline data from Phase 2 clinical study of NS002
- Nasus Pharma Shareholders Approve Capital Increase and Amended Articles at March 5 Meeting